Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nectar Study: NALIRIFOX as Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer
NCT06821997Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan, oxaliplatin, fluorouracil, folinic acid in pancreatic ductal adenocarcinoma (PDAC), sponsored by Roswell Park Comprehensive Cancer Center. Started Mar 2026; status: recruiting.
02
Drugs
nanoliposomal irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06821997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821997.